Literature DB >> 3521271

Concept of empiric therapy with antibiotic combinations. Indications and limits.

J Klastersky.   

Abstract

It appears that the use of antibiotic combinations, especially synergistic ones, is indicated for the management of gram-negative bacillary sepsis in granulocytopenic patients. Synergism is a valuable factor in increasing the serum bactericidal activity, which is highly likely to be important for a favorable outcome in these infections. The potential side effects of antimicrobial combinations should not deter clinicians from their use. The most frequently used combinations for gram-negative bacillary infections are those involving beta-lactams and aminoglycosides. Other potentially synergistic combinations exist as well; however, the clinical experience with these combinations is limited, and, as with double beta-lactam combinations, their potential for antagonism necessitates care when using them. Besides gram-negative bacillary sepsis in granulocytopenic patients, severe staphylococcal infections might represent an indication for the use of combination therapy, especially in patients with compromised mechanisms of defense against infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521271

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.

Authors:  N Krivoy; S Postovsky; R Elhasid; M W Ben Arush
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

3.  Antibiotic efficacy is linked to bacterial cellular respiration.

Authors:  Michael A Lobritz; Peter Belenky; Caroline B M Porter; Arnaud Gutierrez; Jason H Yang; Eric G Schwarz; Daniel J Dwyer; Ahmad S Khalil; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 4.  Outpatient therapy for febrile neutropenia: clinical and economic implications.

Authors:  Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients.

Authors:  T M Bianco; P N Dwyer; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.

Authors:  I R Nováková; J P Donnelly; B E de Pauw
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

9.  Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients.

Authors:  S M Kelsey; B Weinhardt; P W Collins; A C Newland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

Review 10.  Infections in cancer patients: some controversial issues.

Authors:  S C Schimpff; D A Scott; J C Wade
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.